ARA-290 (Cibinetide)
ARA-290 was engineered to reproduce a small structural motif of erythropoietin's tertiary fold — the helix B region — without activating the classical erythropoietin receptor homodimer, avoiding EPO's...
Sequence
Mechanism of Action
ARA-290 was engineered to reproduce a small structural motif of erythropoietin's tertiary fold — the helix B region — without activating the classical erythropoietin receptor homodimer, avoiding EPO's hematopoietic (red-cell-stimulating) effect. By engaging an EPOR/CD131 heterocomplex instead, it activates anti-inflammatory and cytoprotective signaling studied for neuronal and vascular tissue repair. A blinded, placebo-controlled human trial in patients with sarcoidosis-associated small nerve fiber damage reported improved neuropathic symptoms and increased corneal nerve fiber density after 28 days of dosing.